Removing the highly popular diabetes and obesity medications from the shortage list could limit options for patients who ...

but these therapies are also more expensive. Marketed as Lantidra, it is a cellular therapy drug used to treat type 1 diabetes. Donislecel is an allogeneic (donor) pancreatic islet cell treatment ...